$KROS

$11.33 +$0.05 (0.44%) Close

$KROS Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Company Executives

$KROS Management Team

Mr. Justin Frantz

Head of Investor Relations

Age -

Compensation -

Sex Male

Mr. Jean-Jacques Bienaime

Independent Chairman of the Board

Age 71

Compensation $652.9K USD

Sex Male

Dr. Jasbir Seehra

President

Chief Executive Officer

Director

Age 69

Compensation $6.273M USD

Sex Male

Mr. Keith Regnante

Chief Financial Officer

Age 55

Compensation $2.292M USD

Sex Male

Dr. Lorena Lerner

Chief Scientific Officer

Age 54

Compensation -

Sex Female

Name / Title	Age	Compensation	Sex
Mr. Justin Frantz Head of Investor Relations	-	-	Male
Mr. Jean-Jacques Bienaime Independent Chairman of the Board	71	$652.9K USD	Male
Dr. Jasbir Seehra President Chief Executive Officer Director	69	$6.273M USD	Male
Mr. Keith Regnante Chief Financial Officer	55	$2.292M USD	Male
Dr. Lorena Lerner Chief Scientific Officer	54	-	Female

Board of Directors

From the proxy statement filed Apr 22, 2026

Directors

serving now

Independent

6 of 7

stated in the proxy

Average tenure

5.4 years

from year joined

CEO also chairs the board

Jean-Jacques Bienaimé

Director	Age	On board	Independent	Committees	Other public boards	2025 pay
Jean-Jacques Bienaimé Board chair	72	2024 2 years	Independent	Nominating and Corporate Governance · Chair	Ascendis Pharma A/S, Incyte Corporation, Immunome, Inc.	$259,443
Charles Newton	55	2026 0 years	Independent	None stated	Coherus Oncology, Inc., Novavax Inc.	Not stated
Jasbir Seehra CEO	70	2015 11 years	Not independent	None stated	None stated	Paid as CEO
Nima Farzan	50	2020 6 years	Independent	None stated	None stated	$239,035
Julius Knowles	63	2016 10 years	Independent	None stated	None stated	$239,035
Mary Ann Gray	73	2020 6 years	Independent	None stated	BioAtla, Inc., Compass Therapeutics Inc.	$247,535
Alpna Seth	62	2023 3 years	Independent	None stated	Bio-Techne Corporation, Dr. Reddy's Laboratories	$238,535

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

No related-party transactions disclosed

The proxy filed Apr 22, 2026 describes a review policy but reports no transactions.

Read the policy in the proxy

Comments

Company Executives

$KROS Management Team

Mr. Justin Frantz

Mr. Jean-Jacques Bienaime

Dr. Jasbir Seehra

Mr. Keith Regnante

Dr. Lorena Lerner

Board of Directors

Related-party transactions

No related-party transactions disclosed